Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
SAN DIEGO, Oct. 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented data detailing the baseline characteristics of patients with Parkinson's disease (PD) in the Opicapone Treatment Initiation Open-Label Study (OPTI-ON). The poster (Poster #M193); Parkinson's Disease Patient Characteristics in a U.S. Real-World Study of Opicapone) was presented at the 2022 American Neurological Association Annual Meeting (ANA2022) being held October 22–25.
SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition. These data (abstract #1025) are being shared at the MDS International Congress of Parkinson's Disease and Movement Disorders® September 15-18 in Madrid, Spain.
Bial Portela & Companhia Ontilyv (opicapone) Receives Approval in Europe
Bial Portela's Biologic Optilyv (Opicapone) Receives Approval in Europe
New study investigating impact of ONGENTYS at the MDS Virtual Congress 2021
Portuguese pharma company, BIAL, and global contract development and manufacturing organisation (CDMO), Recipharm, have expanded a long-term agreement for the global manufacturing and supply of BIAL’s proprietary molecule opicapone.